Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Levis

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
Blood|July 22, 2006
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapySteven Knapper, Alan K Burnett, Tim Littlewood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2014
Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemiaMichael R Grunwald, Li-Hui Tseng, Ming-Tseh Lin, et al.
Blood Advances|April 29, 2021
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysisDavid J Young, Bao Nguyen, Ruiqi Zhu, et al.
Leukemia Research|May 19, 2015
Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemiaAshkan Emadi, Mariola Sadowska, Brandon Carter-Cooper, et al.
Molecular Oncology|October 12, 2024
Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemiaTessa S Seale, Li Li, J Kyle Bruner, et al.
Molecular Diagnosis & Therapy|October 9, 2015
A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AMLMing-Tseh Lin, Li-Hui Tseng, Jonathan C Dudley, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|July 13, 2013
Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 geneMing-Tseh Lin, Li-Hui Tseng, Katie Beierl, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2020
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous LeukemiaBenjamin K Tomlinson, Molly M Gallogly, Donna M Kane, et al.
Cancer Research|July 26, 2014
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemiaHayley S Ma, Bao Nguyen, Amy S Duffield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Blood|July 22, 2006
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapySteven Knapper, Alan K Burnett, Tim Littlewood, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2014
Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemiaMichael R Grunwald, Li-Hui Tseng, Ming-Tseh Lin, et al.
Blood Advances|April 29, 2021
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysisDavid J Young, Bao Nguyen, Ruiqi Zhu, et al.
Leukemia Research|May 19, 2015
Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemiaAshkan Emadi, Mariola Sadowska, Brandon Carter-Cooper, et al.
Molecular Oncology|October 12, 2024
Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemiaTessa S Seale, Li Li, J Kyle Bruner, et al.
Molecular Diagnosis & Therapy|October 9, 2015
A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AMLMing-Tseh Lin, Li-Hui Tseng, Jonathan C Dudley, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|July 13, 2013
Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 geneMing-Tseh Lin, Li-Hui Tseng, Katie Beierl, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 23, 2020
A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous LeukemiaBenjamin K Tomlinson, Molly M Gallogly, Donna M Kane, et al.
Cancer Research|July 26, 2014
FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemiaHayley S Ma, Bao Nguyen, Amy S Duffield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemiaJudith E Karp, B Douglas Smith, Mark J Levis, et al.
Pageof 14